1. Home
  2. MHO vs ARQT Comparison

MHO vs ARQT Comparison

Compare MHO & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MHO

M/I Homes Inc.

HOLD

Current Price

$141.17

Market Cap

3.4B

ML Signal

HOLD

Logo Arcutis Biotherapeutics Inc.

ARQT

Arcutis Biotherapeutics Inc.

HOLD

Current Price

$23.75

Market Cap

3.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MHO
ARQT
Founded
1976
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.5B
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
MHO
ARQT
Price
$141.17
$23.75
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$160.00
$34.00
AVG Volume (30 Days)
152.4K
1.6M
Earning Date
04-22-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
88.79
EPS
5.57
0.03
Revenue
$4,417,781,000.00
$376,072,000.00
Revenue This Year
$0.66
$34.85
Revenue Next Year
$6.97
$29.39
P/E Ratio
$25.73
$813.00
Revenue Growth
N/A
91.34
52 Week Low
$116.78
$16.62
52 Week High
$163.66
$31.77

Technical Indicators

Market Signals
Indicator
MHO
ARQT
Relative Strength Index (RSI) 37.51 39.92
Support Level $125.88 $22.73
Resistance Level $155.74 $25.25
Average True Range (ATR) 3.33 0.89
MACD -1.07 -0.05
Stochastic Oscillator 9.11 20.00

Price Performance

Historical Comparison
MHO
ARQT

About MHO M/I Homes Inc.

M/I Homes Inc is an American construction company that focuses on residential construction. It consists of two distinct operations: homebuilding and financial services. The homebuilding operations are spread into the Midwest, Mid-Atlantic, and Southern regions, and the financial services operations support homebuilding operations by providing mortgage loans and title services to the customers of homebuilding operations. Homebuilding operations comprises a predominant portion of the revenue. The company builds homes and communities that target entry-level, move-up, and luxury homebuyers.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

Share on Social Networks: